Quinaprii, initiated after advanced ventricular dilation in patients with chronic infarction, prevents progressive remodeling  by Gaudron, Peter et al.
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Results. There was a strong correlation between "non-invasively" mea- 
sured cardiac output and traditional Invasive technique, that remained over 
time. r 2 = 0.90 (implantation), r ~ =" 0.84 (six and eleven months). 
Conclusions. Repeated "non-invaslve" measurements of cardiac output 
using an Implantabts monitoring system are feasible and has a potential for 
management of patients with severe heart failure. 
Quinapdl, Initiated After Advanced Venff icular 
Dilation in Patients With Chrenlc Infarction, 
Prevents Progressive Remodeling 
Peter Gaudrun, Ingnd Kugtsr, Kai Hu, C. Eillas 1, Georg Ertl. Department of 
Medicine tl Mannhe/m, University of Heidelberg, Germany; 1 Department of 
Medicine II Mannheim, Universily of Regensburg, Germany 
Patients with advanced progressive but not yet symptomatic LV dilation due to 
remote MI are at increased dsk for adverse events. We tested the hypothesis 
that progressive LV dilation in chronic MI can be modified by the angiotensin 
converting enzyme inhibiter quinapdl (Q) even if started years after MI. Of 138 
patients with an MI 1.5 to 5 years before, 25 showed progressive LV dilation 
and were randomized (prospective, double-blind study) to placebo (P) or Q 
(10 to 40 rag/day). At baseline (mean 4. sam), NYHA class was 1.2 -I- 0.2 
and 1.8 4. 0.2, age of M156 -4- 6 and 55 :E 5 months, LV radionuclide jection 
fraction (El=) 35 + 3 and 39 4- 3=/0, end-diastolic volume (gated SPECT) 104 
"4- g and 117 :E 12 ml/m 2, wedge pressure (Swan-Ganz catheter) 10 4. 3 and 
8 4- 3 mmHg in P (n = 13) and Q (n = 12), respectively. Progressive LV dilation 
continued in patients on P, but not on Q (figure; *p < 0.05 vs 0 months, +p 
< 0.05 vs P) while wedge pressure at rest (P: 12 4. 3, Q:9 4. 2 mmHg) did 
not change. Wedge pressure (mmHg) during bicycle exercise (25 Watt) was 
similar at baseline (P:20 ± 3, Q:20 4. 6), but at 12 months lower with Q (17 
4. 4, p < 0.05) compared to P (24 ± 4). 
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Thus, further progression of LV dilation in chronic MI can be prevented by 
quinapril even if started years after ML This m~ly at least in part be due to 
prevention of exercise-induced se in LV tilling pressure. 
~ Patients Alter Small Myocardial Inferotion Are Not 
at Low Risk for  Late Ventricslar Dilation and 
Dysfunction 
Peter Gaudrcn, Ingfid Kugler, Kai Hu, Chdstoph Eilles 1, Georg Ertl. 
Department of Medicine II Mannheim, University of Heidelberg, Germany; 
I Department of Medicine II Mannheim, University of Regensburg, Germany 
Left ventdcular dilation after myocardial infarction (MI) is an independent 
predictor of adverse events and mortality. Asymptomatic patients with small 
MI are considered to be at low dsk for LV dilation and late dysfunction 
and englotonsin converting enzyme (ACE) inhibitors are not recommended 
early after MI, To test this, we prospectively followed 104 asymptomatic 
patients after first MI for 7 years. Exclusions were isohemla, reinfarotion and 
uncontrolled hypertension. At baseline, MI size (cinaangiography) was 7 4. 
1% (mean 4. sam) and 30 -i- 2% and radionuclida ejection fraction (EF) 53 
4. 2% and 30 ± 2% in small (n = 87) and large (n = 27) MI, respectively. 
From 4 days, 4 weeks, 0.5 years, 1,5 years, 3 years until 7 years after MI, 
LV end-diastolic volume index (EDVI), by gated SPECT, shows a biphaslc 
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(fast-slow) in large and a monophasic (slow) kinetic in small MI (figure). This 
slow LV dilation in small MI was, however, followed by late dotedoration of 
EF (4 days: 53 4. 2, 4 weeks: 54.4- 2, 1.5 years: 53 4. 2, 3 years: 49 ± 2, 7 
years: 34:1:3 t, 1" ANOVA p < 0.05 vs. 4 days). 
Thus, even after small MI, the LV may undergo slow but long-term re- 
modeling which may be missed due to the fiat slope of LV volume. Since it 
may precede insidious development of LV failure, even patients with small 
MI should be followed carefully and reconsidered for an ACE inhibitor. 
~ Effect of  Aspirin on the Acute and Chronic 
Hemodynamic Response to  Anqiotensin II 
Receptor B!ockade With Losortan In Heart Failure 
Martin J, Fray, Mary Healy, George Klinger, Jennifer Toh, Ewe Rudnska, 
Heart Center of Sarasota, Sarasota, FL; Merck Research Labs, West Point, 
PA 
Attenfuation of the acute hemedynamtc effects of ACE inhibitors by aspidn 
(A) in patients with heart failure iF) has been reported. Losartan (L), a direct 
angiotensin II receptor antagonist results in a favorable hamodynamic effect 
in F, but the interaction with A is unknown. We reviewed the data from 
our multicenter trial of 134 patienLs with ejection fraction < 40% and wedge 
pressure (PCWP) > 13 mmHg who had invasive hemedynam~c assessments 
after the first dose of L and after 12 weeks of L (2.5, 10, 25, 50 rag). Aspidn 
was taken by 52% in both the acute and chronic study. A high dose L 
subgroup (25 & 50 rag, n = 51) was also reviewed. Results: For the entire 
population, the 5 hour acute and chronic hemodynamics were not attenuated 
by A for heart rate (HR), mean artedal pressure (MAP), mean pulmonary 
pressure (PAP), or systemic vascular esistance (SVR); p = NS by ANCOVA. 
Results of high dose group (25 & 50 mg L) is shown as change from baseline 
(+STD). 
Acute ChmnlQ 
A[n = 22) No-A [n = 29) Atn = 20) No-A(n = 23) 
MAP -4.8 4- 8.0 -7.2 ± 6.4 -3.1 +6.3 -6.7 4- 7.2 
PAP -3.8-4- 3.4 -3.7 4- 4.5 -2.3+9.0 -6.9 :t: 7.2 
PCWP -4.04. 3.7 -3.74- 4.7 -3.S+8.7 -4.1 4- 5.7 
Conclusions: In this study population, A does not appear to result in a 
consistent attenuation of the hemodynamtc effect of L in patients with F after 
beth acute and chronic treatment. 
~ I s  Monotherepy With ACE Inhibit ion Preferable to 
Diuretics in Mild Heart Fai lure? A Comparison of  
Benazepdl end Hydrochlorothlazide 
Willem J. Remme, Frdddric Bodin, on behalf of the Benazepril Heart Failure 
Study Group. Sticares Foundation, Rotterdam, The Netherlands 
Theoretically, in mild heart failure without overt fluid retention ACE inhibition 
may be preferable to diuretics as monotherapy. As no comparative data 
exist, benazepdl(B, n = 192) and hydrochlorothiazlde (H, n = 195) patients 
(pts) with eady, mild heart failure (NYHA ci II) due to Isohemlc or idiopathic 
dilated cardlomyopathy were compared during a 3-month doubts-blind, par- 
ailel study. After withdrawal of diuretics, if present, and > 2 days placebo, pta 
were randomised to 2 mg B or 12.5 mg H daily, with uptitration to 10 mg and 
50 mg daily, rasp., during the first month, and addition of the altomaflve treat- 
ment thereafter if necessary. Efficacy endpolnta included bicycle exercise 
duration, NYHA class rating, discontinuation (worsening heart falfum;~ and 
LV end diastolic dimension and fractional shortening (echo), assessed at 4, 
8 and 12 weeks. Baseline critsria were comparable. In each group, 1/3 had 
never received diuretics and 1/3 continued digitalis glycosides (unchanged 
doses) for tachyarrhythmia control. 49% of pts remained on first-line medi- 
cation alone, 50 B and 55 H pts requiring the highest dose. 33 B and 29 H 
pts discontinued due to worsening of failure or cardiac death, 8 and 6 and 
2 and 1 B and H pts, rasp. Exercise duration increased similarly, from 423 
to 491 sec (B) and from 414 to 491 sea (H). 42% and 43% of B and H pts 
improved one NYHA class. Few pls detoddrated. Body weight did not change 
in either group. Neither drug significantly affected LV dimensions or function. 
Overall, side effects were comparable, However, hypokalemia (< 3.4 retool/l) 
and worsening of renal function (increase creatinlne > 30%) occurred in 15 
and 14 H vs 2 and 8 B pts, resto. Whereas efficacy and general tolerabllity 
of monotherapy with B and H are comparable, electrolyte and renal function 
abnormalities prevail in H, which, in addition to neurohormonal stimulatincl 
properties ~.f diuretics, favours ACE inhthitor monotherapy (benazepdl) in 
mild heart failure without overt fluid retention. 
